With the help of UniQuest, Dendright negotiated and closed a research collaboration deal with Janssen Biotech, Inc. in 2012. In 2013, Janssen Biotech, Inc entered into a larger R&D collaboration with Dendright which included an option to license agreement for the rheumatoid arthritis immunotherapy.